In this study we could also show that HER2 status was one of the variables affecting CD169+ LNM macrophages as prognostic marker in multivariable analyses [15], a finding that was not supported using a different breast cancer cohort [21]. The gene discussed is SIGLEC1; the disease is breast carcinoma.